Et forsøg for at lære, hvor effektivt og sikkert Odronextamab er sammenlignet med standardbehandling for voksne deltagere med tidligere behandlet aggressivt B-celle non-Hodgkin lymfom (OLYMPIA-4)
Et fase 3, randomiseret, åbent label-studie, der evaluerer effektiviteten og sikkerheden af Odronextamab (REGN1979), et anti-CD20 x anti-CD3 bispecifikt antistof, versus standardbehandlingsterapi hos deltagere med recidiverende/refraktært aggressivt B-celle non-Hodgkin lymfom (OLYMPIA-4)
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as 'refractory') or has returned (also known as 'relapsed'). The aim of the study is to see how safe, tolerable and effective the study drug is when given alone.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug versus Standard of Care (SOC)
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
- Comparing the impact from the study drug versus SOC on quality-of-life and ability to complete routine daily activities
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Córdoba, Argentina, X5000JHQ
- Sanatorio Allende
-
Córdoba, Argentina, X5016KEH
- Hospital Privado Universitario de Cordoba
-
-
Buenos Aires
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, 1118
- Hospital Aleman
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, 1426
- Instituto Alexander Fleming
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, 1280
- Hospital Britanico de Buenos Aires
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1114AAN
- Fundaleu - Fundacion Para Combatir La Leucemia
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1199ABB
- Hospital Italiano de Buenos Aires
-
La Plata, Buenos Aires, Argentina, B1900AUR
- Hospital Italiano de La Plata
-
San Juan Bautista, Buenos Aires, Argentina, B1888AAE
- Hospital Alta Complejidad El Cruce
-
-
-
-
Queensland
-
Woolloongabba, Queensland, Australien, 4102
- Princess Alexandra Hospital
-
-
Victoria
-
Heidelberg, Victoria, Australien, 3084
- Olivia Newton John Cancer Wellness & Research Centre
-
-
-
-
-
Rio de Janeiro, Brasilien, 20231050
- Instituto Nacional de Cancer Jose Alencar Gomes da Silva
-
São Paulo, Brasilien, 08270-070
- Casa de Saude Santa Marcelina
-
São Paulo, Brasilien, 01321000
- A Beneficencia Portuguesa de Sao Paulo, Oncology House
-
São Paulo, Brasilien, 05403-000
- Hospital das Clinicas, Faculty of Medicine, University of Sao Paulo
-
São Paulo, Brasilien, 01308-050
- Hospital Sirio Libanes
-
São Paulo, Brasilien, 04501-000
- Instituto D'Or De Pesquisa e Ensino
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien, 41950-640
- Ensino e Terapia de Inovacao Clinica Amo (Etica)
-
Salvador, Estado de Bahia, Brasilien, 40285-000
- Hospital Sao Rafael
-
Salvador, Estado de Bahia, Brasilien, 40050-410
- Hospital Santa Izabel - Santa Casa de Misericordia da Bahia
-
-
Federal District
-
Brasília, Federal District, Brasilien, 70200-730
- Hospital Sirio Libanes Brasilia
-
-
Paraná
-
Cascavel, Paraná, Brasilien, 85806-300
- Uopeccan Hospital do Cancer de Cascavel
-
Curitiba, Paraná, Brasilien, 81520-060
- Hospital Erasto Gaertner
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien, 90035-903
- Hospital de Clinicas de Porto Alegre
-
Porto Alegre, Rio Grande do Sul, Brasilien, 90110-270
- Centro Gaucho Integrado
-
-
São Paulo
-
Jaú, São Paulo, Brasilien, 17210-080
- Amaral Carvalho Hospital
-
-
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chile, 7500921
- Fundacion Arturo Lopez Perez
-
Santiago, Santiago Metropolitan, Chile, 7650620
- Clinica Alemana de Santiago
-
-
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 050034
- Hospital Pablo Tobon Uribe
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760042
- Clinica Imbanaco
-
-
-
-
Johor
-
Johor Bahru, Johor, Malaysia, 80100
- Hospital Sultanah Aminah Jhor Bahru
-
-
Kuala Lumpur
-
Kuala Lumpur, Kuala Lumpur, Malaysia, 59100
- University Malaya Medical Centre
-
-
Sabah
-
Kota Kinabalu, Sabah, Malaysia, 88586
- Hospital Queen Elizabeth
-
-
Selangor
-
Kuala Lumpur, Selangor, Malaysia, 68000
- Hospital Ampang
-
Subang Jaya, Selangor, Malaysia, 47500
- Subang Jaya Medical Center
-
-
-
-
Bucharest
-
Bucharest, Bucharest, Rumænien, 030141
- Coltea Clinical Hospital
-
-
Cluj
-
Cluj-Napoca, Cluj, Rumænien, 400015
- Ion Chiricuta Oncology Institute
-
-
-
-
-
Singapore, Singapore, 119074
- National University Hospital Singapore
-
-
-
-
-
Madrid, Spanien, 28034
- Hospital Universitario Ramon y Cajal
-
Pamplona, Spanien, 31008
- Clinica Universidad de Navarra- Pamplona
-
Valencia, Spanien, 46009
- Instituto Valenciano de Oncologia
-
-
Balearic Islands
-
Palma, Balearic Islands, Spanien, 07120
- Hospital Universitari Son Espases
-
-
-
-
-
Busan, Sydkorea, 49201
- Dong-A University Hospital
-
Busan, Sydkorea, 49241
- Pusan National University Hospital
-
Daegu, Sydkorea, 42601
- Keimyung University Dongsan Hospital
-
Seoul, Sydkorea, 05505
- Asan Medical Center
-
Seoul, Sydkorea, 07345
- Yeouido St. Marys Hospital
-
Seoul, Sydkorea, 06591
- Seoul St Marys Hospital
-
Ulsan, Sydkorea, 44033
- Ulsan University Hospital
-
-
Gyeonggi-do
-
Gyeonggi-do, Gyeonggi-do, Sydkorea, 10408
- National Cancer Center
-
Suwon, Gyeonggi-do, Sydkorea, 16247
- St. Vincent Hospital - The Catholic University of Korea
-
-
Gyeongsangnam-do
-
Yangsan, Gyeongsangnam-do, Sydkorea, 50612
- Pusan National University Yangsan Hospital
-
-
Jeollabuk-do
-
Jeonju, Jeollabuk-do, Sydkorea, 54907
- Jeonbuk National University Hospital
-
-
Namdong-Gu
-
Incheon, Namdong-Gu, Sydkorea, 21565
- Gachon University Gil Medical Center
-
-
-
-
-
Changhua, Taiwan, 500-06
- Changhua Christian Hospital
-
Changhua, Taiwan, 50008
- Show Chwan Memorial Hospital
-
Kaohsiung City, Taiwan, 80756
- Kaohsiung Medical University Hospital
-
Kaohsiung City, Taiwan, 83301
- Chang Gung Memorial Hospital Kaohsiung
-
Taichung, Taiwan, 40705
- Taichung General Veterans Hospital
-
Tainan, Taiwan, 704
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 10002
- National Taiwan University Hospital
-
Taipei, Taiwan, 11490
- Tri-Service General Hospital
-
-
Hunan Province
-
Taoyuan, Hunan Province, Taiwan, 33305
- Chang Gung Memorial Hospital - Linkou Branch
-
-
-
-
-
Bangkok, Thailand, 10330
- Chulalongkorn University
-
Bangkok, Thailand, 10700
- Sriraj Hospital
-
Chiang Mai, Thailand, 50200
- Chiang Mai University
-
Khon Kaen, Thailand, 40002
- Khon Kaen University
-
-
-
-
-
Ankara, Tyrkiet (Türkiye), 06100
- Sbu Dr.A.Y. Ankara Onkoloji Suam
-
Istanbul, Tyrkiet (Türkiye), 34365
- VKV American Hopital
-
Istanbul, Tyrkiet (Türkiye), 34418
- Istanbul University
-
Izmir, Tyrkiet (Türkiye), 35100
- Ege University
-
Sakarya, Tyrkiet (Türkiye), 54290
- Sakarya University Medical Faculty
-
Samsun, Tyrkiet (Türkiye), 55270
- Ondokuz Mayıs University
-
Zonguldak, Tyrkiet (Türkiye), 67600
- Zonguldak Bulent Ecevit University
-
-
Ankara
-
Mamak, Ankara, Tyrkiet (Türkiye), 06620
- Ankara University Faculty of Medicine
-
-
Central Anatolia
-
Ankara, Central Anatolia, Tyrkiet (Türkiye), 06100
- Gazi University
-
-
Mersin
-
Mezitli, Mersin, Tyrkiet (Türkiye), 33200
- VM Medical Park Mersin Hospital
-
-
Suleymanpasa
-
Tekirdağ, Suleymanpasa, Tyrkiet (Türkiye), 59100
- Tekirdag Namik Kemal University Hospital
-
-
-
-
-
Budapest, Ungarn, 1088
- Semmelweis University
-
-
Baranya
-
Pécs, Baranya, Ungarn, 7624
- University of Pecs
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Ungarn, 4032
- Debreceni Egyetem
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Histologically proven aggressive B-NHL, as described in the protocol. Availability of tumor tissue for submission to central laboratory is required for study enrollment. Archival tumor tissue for histological assessment prior to enrollment is allowed
- Have primary refractory or relapse 12 months or less (≤) from initiation of frontline therapy Only participants who received 1 prior line of therapy containing an anti-Cluster of Differentiation 20 (CD20) antibody and anthracycline are allowed for enrollment
- Have measurable disease with at least one nodal lesion with longer diameter (LDi) greater than 1.5 cm or at least one extranodal lesion with LDi greater than 1.0 cm, documented by diagnostic imaging (computed tomography [CT] or magnetic resonance imaging [MRI])
- Intent to proceed to autologous stem cell transplant (ASCT), as described in the protocol
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Adequate hematologic and organ function.
Key Exclusion Criteria:
- Primary central nervous system (CNS) lymphoma or known involvement by non-primary CNS NHL, as described in the protocol
- History of or current relevant CNS pathology, as described in the protocol
- A malignancy other than NHL unless the participant is adequately and definitively treated and is cancer free for at least 3 years, with the exception of localized prostate cancer, cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer that was definitively treated
- Any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol
- Wash-out period from prior anti-lymphoma treatments and infections, as described in the protocol
- Allergy/hypersensitivity to study drug, or excipients.
NOTE: Other protocol defined inclusion / exclusion criteria apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Odronextamab
Participants will receive odronextamab monotherapy. |
Administered by intravenous (IV) infusion
Andre navne:
|
|
Aktiv komparator: Standard Of Care
Participants will receive salvage therapy (ifosfamide, carboplatin, etoposide ± rituximab [ICE ± R], or dexamethasone, cisplatin, cytarabine ± rituximab [DHAP ± R], or gemcitabine, dexamethasone, cisplatin ± rituximab [GDP ± R]) and continue with autologous stem cell transplant (ASCT) following a complete response (CR)/partial response (PR). |
Administered by IV infusion, as part of the ICE ± R salvage therapy
Andre navne:
Administered by IV infusion, as part of the ICE ± R salvage therapy
Andre navne:
Administered by IV infusion, as part of the ICE ± R salvage therapy
Andre navne:
Administered by IV infusion, as part of the ICE ± R, or DHAP ± R, or GDP ± R salvage therapy.
Andre navne:
Administered by IV, or orally (PO) as part of the DHAP ± R, or GDP ± R salvage therapy.
Andre navne:
Administered by IV infusion, as part of the DHAP ± R or GDP +/-R salvage therapy.
Andre navne:
Administered by IV infusion, as part of the DHAP ± R salvage therapy.
Andre navne:
Administered by IV infusion, as part of the GDP ± R salvage therapy.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Event-Free Survival (EFS) as assessed by independent central review (ICR)
Tidsramme: Assessed up to 3 years
|
Assessed up to 3 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
EFS vurderet af lokal efterforsker
Tidsramme: Vurderet op til 3 år
|
Vurderet op til 3 år
|
|
|
PFS vurderet af lokal efterforsker
Tidsramme: Vurderet op til 3 år
|
Vurderet op til 3 år
|
|
|
BOR vurderet af lokal efterforsker
Tidsramme: Vurderet op til 6 måneder
|
Vurderet op til 6 måneder
|
|
|
CR vurderet af lokal efterforsker
Tidsramme: Vurderet op til 6 måneder
|
Vurderet op til 6 måneder
|
|
|
DOR vurderet af lokal efterforsker
Tidsramme: Vurderet op til 3 år
|
Vurderet op til 3 år
|
|
|
Sværhedsgraden af TEAE'er
Tidsramme: Vurderet op til 1 år
|
Vurderet op til 1 år
|
|
|
Odronextamab-koncentrationer i serum
Tidsramme: Vurderet op til 6 måneder
|
Vurderet op til 6 måneder
|
|
|
Responsens varighed (DOR) vurderet af ICR
Tidsramme: Vurderet op til 3 år
|
Vurderet op til 3 år
|
|
|
Progression Free Survival (PFS) as assessed by ICR
Tidsramme: Assessed up to 3 years
|
Assessed up to 3 years
|
|
|
Best Overall Response (BOR) as assessed by ICR
Tidsramme: Assessed up to 6 months
|
Assessed up to 6 months
|
|
|
Overall Survival (OS)
Tidsramme: Assessed up to 3 years
|
Assessed up to 3 years
|
|
|
Overall change in physical functioning as measured by scores of the physical function scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC-QLQ-C30)
Tidsramme: Assessed up to 3 years
|
The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Assessed up to 3 years
|
|
Complete Response (CR) as assessed by ICR
Tidsramme: Assessed up to 6 months
|
Assessed up to 6 months
|
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: Assessed up to 1 year
|
Assessed up to 1 year
|
|
|
Occurrence of Anti-Drug Antibodies (ADAs) to odronextamab
Tidsramme: Assessed up to 6 months
|
Assessed up to 6 months
|
|
|
Magnitude of ADAs to odronextamab
Tidsramme: Assessed up to 6 months
|
Assessed up to 6 months
|
|
|
Measurable Residual Disease (MRD) status
Tidsramme: Assessed up to 6 months
|
Assessed up to 6 months
|
|
|
Overall change in Patient-Reported Outcomes (PROs), as measured by scores of the EORTCQLQ- C30
Tidsramme: Assessed up to 3 years
|
The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Assessed up to 3 years
|
|
Overall change in PROs, as measured by scores of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-LymS)
Tidsramme: Assessed up to 3 years
|
The FACT-Lym lymphoma subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life. |
Assessed up to 3 years
|
|
Overall change in PROs, as measured by scores of the EuroQol-5 Dimension-5 Level Scale (EQ-5D-5L)
Tidsramme: Assessed up to 3 years
|
The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state". |
Assessed up to 3 years
|
|
Overall change in score of the Global Population item 5 (GP5) of the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire
Tidsramme: Assessed up to 3 years
|
A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4). |
Assessed up to 3 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neoplasmer
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Lymfesygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom
- Hemiske og lymfatiske sygdomme
- Lymfom, B-celle
- Lymfom, Non-Hodgkin
- Aminosyrer, peptider og proteiner
- Proteiner
- Svovlforbindelser
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Nukleinsyrer, nukleotider og nukleosider
- Kulbrinter
- Kulbrinter, cyklisk
- Kulhydrater
- Podophyllotoxin
- Tetrahydronaphthalenes
- Naphthalenes
- Polycykliske aromatiske kulbrinter
- Kulbrinter, aromatisk
- Polycykliske forbindelser
- Glukosider
- Glycosider
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Uorganiske kemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Koordinationskomplekser
- Deoxycytidin
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Gravidier
- Graviditet
- Steroider
- SMUSED-RING-forbindelser
- Steroider, fluoreret
- Benzenderivater
- Sulfonsyrer
- Svovlsyrer
- Fosforamid -sennep
- Nitrogen sennepsforbindelser
- Sennepsforbindelser
- Kulbrinter, halogeneret
- Phosphoramider
- Organophosphorforbindelser
- Nukleosider
- Gravideretrioler
- Arabinonucleosider
- Platinforbindelser
- Antistoffer, monoklonal, murint afledt
- Oxaziner
- Benzenesulfonater
- Arylsulfonater
- Arylsulfonsyrer
- Cyclophosphamid
- Rituximab
- Gemcitabin
- Dexamethason
- Cytarabin
- Etoposid
- Carboplatin
- Cisplatin
- Ifosfamid
- Calciumdobesilat
- Etoposidphosphat
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- R1979-HM-2299
- 2022-502783-21-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD-delingstidsramme
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD-delingsadgangskriterier
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .